aTyr Pharma, Inc. is a biotherapeutics company. The Company focuses on the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a discovered set of physiological modulators. It focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company's lead candidate, Resolaris, is an intravenous protein therapeutic for the treatment of myopathies with an immune component. Resolaris is in a Phase Ib/II clinical trial in adult patients with FSHD; a Phase Ib/II trial in adult patients with LGMD 2B or FSHD, and a Phase Ib/II trial in patients with early onset FSHD. As of September 30, 2015, the Company had not generated any revenues.